N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors

Sandwich Chemistry Department, Pfizer Global Research and Development, Sandwich Labs, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK.
Bioorganic & Medicinal Chemistry Letters (Impact Factor: 2.42). 05/2007; 17(7):2022-5. DOI: 10.1016/j.bmcl.2007.01.020
Source: PubMed


A series of N-benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amine monoamine reuptake inhibitors are described. Selective dual 5-HT and NA reuptake inhibition was achieved, and analogues with weak CYP2D6 inhibition, good human in vitro metabolic stability and wide ligand selectivity, such as 12b, were identified.

1 Read
  • [Show abstract] [Hide abstract]
    ABSTRACT: Depression is a major psychiatric disorder. It affects millions of people worldwide and inflicts tremendous economic burden on societies. The advent of selective serotonin re-uptake inhibitors as antidepressants has been a revolutionary advance in the treatment of depression and related disorders. However, selective serotonin re-uptake inhibitors are also associated with several undesirable properties, such as delayed onset of action, low response rate and side effects. The present search for a newer generation of antidepressants is focused on overcoming these issues. The patent literature covered in this review, during 2004 - 2006, illustrates several strategies employed by the pharmaceutical industry in the development of enhanced serotonin re-uptake inhibitors. Encouraged by the success of venlafaxine and duloxetine, several companies have pursued dual-acting serotonin and noradrenaline re-uptake inhibitors as drug candidates for depression treatment. Molecules with combined serotonin re-uptake inhibitor and 5-HT autoreceptor (5-HT(1A) and/or 5-HT(1B)) antagonist properties are being developed. In particular, recent research suggests that serotonin 5-HT(1B) antagonists alone or combined with selective serotonin re-uptake inhibitors might hold unique promise as efficacious antidepressants. Finally, efforts are underway to formulate new drug candidates with both serotonin re-uptake inhibitor and neurokinin 1 (NK(1)) antagonist activities. Despite mixed results from clinical trials with several NK(1) antagonists, effective therapeutic agents for depression may still emerge from compounds with combined serotonin reuptake inhibitor/NK(1) antagonist properties.
    Expert Opinion on Therapeutic Patents 08/2007; 17(8):889-907. DOI:10.1517/13543776.17.8.889 · 4.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel series of 1-(2-phenoxyphenyl)methanamines is disclosed, which possess selective dual 5-HT and NA reuptake pharmacology. Analogues with good human in vitro metabolic stability, hERG selectivity and passive membrane permeability were identified.
    Bioorganic & medicinal chemistry letters 02/2008; 18(2):596-9. DOI:10.1016/j.bmcl.2007.11.080 · 2.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: [4-(Phenoxy)pyridine-3-yl]methylamines are disclosed as a new series of selective noradrenaline reuptake inhibitors (NRI). Structure-activity relationships established that potent NRI activity could be achieved by appropriate substitution at the 2-position of the phenoxy ring. Compound 31 demonstrated potent NRI activity combined with good selectivity over serotonin and dopamine reuptake and no significant off-target pharmacology.
    Bioorganic & medicinal chemistry letters 04/2008; 18(6):1795-8. DOI:10.1016/j.bmcl.2008.02.036 · 2.42 Impact Factor
Show more